Name | Lamivudine + Zidovudine |
Classes |
Antiviral Agent Antiviral Combination Antiinfective Agent |
Diseases |
Bangla
Lamivudine + Zidovudine
Lamivudine + Zidovudine is a combination of two nucleoside reverse transcriptase inhibitor. Both Lamivudine & Zidovudine are nucleoside analogs which are incorporated to the viral DNA during replication and inhibit the process terminating viral replication.
Lamivudine + Zidovudine is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
- Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily.
- Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily.
- Because Lamivudine + Zidovudine is a fixed-dose tablet and cannot be dose adjusted, Lamivudine + Zidovudine is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose-limiting adverse reactions.
- Hematologic Toxicity: The use of zidovudine, a component of Lamivudine + Zidovudine, has been linked to hematologic toxicity, including neutropenia and anemia.
- Myopathy: Symptomatic myopathy associated with prolonged use of zidovudine.
- Exacerbations of Hepatitis B: Lactic Acidosis and Severe Hepatomegaly with Steatosis: The use of nucleoside analogues has been linked to lactic acidosis and severe hepatomegaly with steatosis, including fatal cases.
- Patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have stopped taking lamivudine, a component of Lamivudine + Zidovudine, have experienced severe acute exacerbations of hepatitis B. In these patients, closely monitor hepatic function and, if necessary, initiate anti-hepatitis B treatment.
-
In HIV-1/HCV co-infected patients receiving combination antiretroviral therapy and interferon alfa with/without ribavirin, hepatic decompensation, some fatal, has occurred. Discontinue lamivudine and zidovudine tablets as needed, and consider reducing or discontinuing interferon alfa, ribavirin, or both.
-
Anemia has been reported to worsen in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine. Ribavirin and zidovudine should not be taken together.
-
In patients with a history of pancreatitis or other significant risk factors for pancreatitis, use with caution. As clinically indicated, discontinue treatment.
-
In patients receiving combination antiretroviral therapy, immune reconstitution syndrome and redistribution/accumulation of body fat have been reported.
Contraindication
Contraindicated in patients with a previous hypersensitivity reaction to-
None known.
None known.